The treatment with anti-HER2 drugs in BC patients is primarily based on HER2 protein overexpression established by immunohistochemistry (IHC) method, while “dual-probe in situ” hybridization (SISH) is used in case of HER2 with equivocal immunohistochemical score (IHC 2+). Here, ERBB2 is linked to breast cancer.